Ascentage Pharma Announces Secondary Offering on Nasdaq, Expanding Global Reach
China-based Ascentage Pharma (HKG: 6855) has unveiled plans for a secondary offering of up to...
Auzone Submits NDA for Oral Edaravone TTYP01 to Treat ALS
Auzone Biological Technology has announced the submission of a New Drug Application (NDA) for its...
Pediatrix Therapeutics’ Neffy NDA Accepted by NMPA for Allergy Treatment
China-based Pediatrix Therapeutics has announced that the New Drug Application (NDA) for its neffy (epinephrine...
Immunochina Pharmaceuticals and Cell Store Partner to Advance Cell Therapy Commercialization in China
Beijing-based firms Immunochina Pharmaceuticals and Cell Store have announced a strategic partnership aimed at bolstering...
Hinova Pharmaceuticals Enrolls First Patient in Phase II Study for HP518 in mCRPC
China-based biopharma Hinova Pharmaceuticals has announced the enrollment of the first patient in an open,...
Xbiome Partners with ZoHealth to Advance Microbiome Drug Development and Precision Nutrition
China-based Xbiome, an AI-driven microbiome drug development company, has announced a strategic alliance with Australia-headquartered...
Astellas Pharma Partners with Axcelead DDP for Targeted Protein Degraders Discovery
Japan-based Astellas Pharma Inc. (TYO: 4503) has struck an accord with compatriot firm Axcelead Drug...
AusperBio Secures $73 Million in Series B Financing to Advance Hepatitis B Therapy
Sino-US liver therapy developer AusperBio has announced the completion of a USD 73 million Series...
Advaccine Biotechnology’s MICROEPAD Receives FDA Registration Approval
China-based vaccine developer Advaccine Biotechnology has announced receiving registration approval from the US Food and...
Shandong Buchang Pharmaceuticals Terminates Agreement with NOVAST Laboratories
China-based Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858) has announced the termination of the development,...
Chia Tai Tianqing’s Benmelstobart and Anlotinib Combo Meets Primary Endpoint in Phase III Study
China-based Chia Tai Tianqing Pharmaceutical, a subsidiary of Sino Biopharmaceutical Ltd (HKG: 1177), has announced...
China Isotope & Radiation Corporation’s [18F] Piramide Receives NMPA Clinical Trial Approval
On December 24, 2024, China Isotope & Radiation Corporation (HKG: 1763) announced that its subsidiary,...
Hybio Pharmaceutical Receives US FDA Approval for Biosimilar Victoza (Liraglutide)
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has announced receiving official approval from the US...
Shanxi C&Y Pharmaceutical Initiates Clinical Study for Generic Ferric Maltol with NMPA Approval
China’s Shanxi C&Y Pharmaceutical Group Co., Ltd (SHE: 300254) has announced the initiation of a...
Boji Medical Technology Receives NMPA Approval for TBA Clinical Study in Drug-Resistant Tuberculosis
China-based Clinical Research Organization (CRO) Boji Medical Technology Co., Ltd. (SHE: 300404) has announced receiving...
Jiangsu Hengrui Pharmaceuticals Secures NMPA Approvals for Prostate Cancer and Solid Tumor Clinical Trials
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving separate clinical trial approvals from...
Sichuan Biokin’s BL-M08D1 and CSPC’s SYS6010 Eye Breakthrough Therapy Designations in China
The China’s Center for Drug Evaluation (CDE) website has indicated that China-based Sichuan Biokin Pharmaceutical...
CDE Indicates Priority Review for Boehringer Ingelheim’s Zongertinib and Peers
The China’s Center for Drug Evaluation (CDE) website has indicated that several drugs, including German...
Zelgen Biopharmaceuticals’ ZG005 Gets NMPA Green Light for Solid Tumor and Lymphoma Clinical Trial
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced receiving clinical approval from the National...
Western Chongqing Southern Sichuan Precision Medicine Center Digital Platform Launches in Rongchang District
On December 24, the Western Chongqing Southern Sichuan Precision Medicine Center Digital Information Platform was...